The bottleneck at Vascular Genetics

The pace of Vascular Genetics Inc.'s Phase I/II trials of its VEGF-2 gene therapy in coronary artery disease and critical limb ischemia has out-distanced the company's ability to develop an assay for the protein in patients, prompting the FDA